Durvalumab is a PD-L1-targeting immunosuppressant that the European Medicines Agency approved for the consolidation of locally advanced PD-L1-positive NSCLC following chemoradiotherapy [156]. Here, CD274 is linked to non-small cell lung carcinoma.